Skip to main content
. 2013 Jun 1;6(3):363–369. doi: 10.1593/tlo.13166

Figure 3.

Figure 3

(A) First-line PFS stratified by KRAS mutational status in patients with first-line oxaliplatin-based regimens. (B) First-line PFS stratified by KRAS mutational status in patients with first-line irinotecan-based regimens. (C) OS stratified by KRAS mutational status in patients with first-line oxaliplatin-based regimens. (D) OS stratified by KRAS mutational status in patients with first-line irinotecan-based regimens.